IL148079A0 - Human ctla-4 antibodies and compositions containing the same - Google Patents

Human ctla-4 antibodies and compositions containing the same

Info

Publication number
IL148079A0
IL148079A0 IL14807900A IL14807900A IL148079A0 IL 148079 A0 IL148079 A0 IL 148079A0 IL 14807900 A IL14807900 A IL 14807900A IL 14807900 A IL14807900 A IL 14807900A IL 148079 A0 IL148079 A0 IL 148079A0
Authority
IL
Israel
Prior art keywords
antibodies
same
compositions containing
human ctla
human
Prior art date
Application number
IL14807900A
Other languages
English (en)
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of IL148079A0 publication Critical patent/IL148079A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
IL14807900A 1999-08-24 2000-08-24 Human ctla-4 antibodies and compositions containing the same IL148079A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15045299P 1999-08-24 1999-08-24
PCT/US2000/023356 WO2001014424A2 (en) 1999-08-24 2000-08-24 Human ctla-4 antibodies and their uses

Publications (1)

Publication Number Publication Date
IL148079A0 true IL148079A0 (en) 2002-09-12

Family

ID=22534598

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14807900A IL148079A0 (en) 1999-08-24 2000-08-24 Human ctla-4 antibodies and compositions containing the same
IL148079A IL148079A (en) 1999-08-24 2002-02-10 Human CTLA-4 antibodies and preparations containing them
IL189629A IL189629A0 (en) 1999-08-24 2008-02-20 Compositions containing human ctla-4 antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL148079A IL148079A (en) 1999-08-24 2002-02-10 Human CTLA-4 antibodies and preparations containing them
IL189629A IL189629A0 (en) 1999-08-24 2008-02-20 Compositions containing human ctla-4 antibodies

Country Status (22)

Country Link
US (1) US6984720B1 (ru)
EP (4) EP3214175A1 (ru)
JP (4) JP4093757B2 (ru)
KR (3) KR100996759B1 (ru)
CN (2) CN102766210B (ru)
AT (1) ATE354655T1 (ru)
AU (3) AU784012B2 (ru)
BE (1) BE2012C001I2 (ru)
CA (2) CA2589418A1 (ru)
CY (2) CY1107628T1 (ru)
DE (2) DE60033530T2 (ru)
DK (1) DK1212422T3 (ru)
ES (1) ES2282133T3 (ru)
FR (1) FR12C0004I2 (ru)
HK (1) HK1048831A1 (ru)
IL (3) IL148079A0 (ru)
LU (1) LU91928I2 (ru)
MX (1) MXPA02001911A (ru)
NZ (1) NZ517202A (ru)
PT (1) PT1212422E (ru)
WO (1) WO2001014424A2 (ru)
ZA (1) ZA200201190B (ru)

Families Citing this family (964)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK1137436T3 (da) * 1998-12-03 2008-10-13 Univ California Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
KR100849443B1 (ko) * 1998-12-23 2008-07-31 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (es) * 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7323311B2 (en) 2000-03-03 2008-01-29 Cambridge Antibody Technology Limited Methods of obtaining a specific binding member that binds eotaxin
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US7452535B2 (en) * 2002-04-12 2008-11-18 Medarex, Inc. Methods of treatment using CTLA-4 antibodies
EP1503795A4 (en) * 2002-05-02 2009-01-21 Univ Connecticut Health Ct USE OF HOT SHOCK PROTEINS TO INCREASE THE EFFICACY OF ANTIBODY THERAPEUTICS
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2709103T3 (es) 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
CA2498264A1 (en) * 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
WO2004029069A2 (en) * 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
KR101348472B1 (ko) 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
US7378503B2 (en) 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US7465446B2 (en) * 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2528549A1 (en) * 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
AU2004298492B2 (en) 2003-12-10 2011-08-18 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
NZ548821A (en) 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
AU2005258336A1 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
WO2006101503A2 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
AU2005258077C1 (en) 2004-06-21 2012-10-25 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1827470A2 (en) * 2004-12-09 2007-09-05 Neuro Therapeutics AB Materials and methods related to dickkopfs (dkk) and neurogenesis
CN101155832B (zh) * 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
BRPI0608815B1 (pt) * 2005-03-08 2021-10-13 Pfizer Products Inc Composições de anticorpo anti-ctla-4
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
AU2006227879A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
DE102005019845A1 (de) * 2005-04-28 2006-11-02 Li-Te Chin Neue aus humanen Keimbahnsequenzen gewonnene Antikörperstrukturen
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN103830725A (zh) 2005-06-08 2014-06-04 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
JP2009500412A (ja) * 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
EP2397496A3 (en) * 2005-07-18 2013-05-29 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
NL1029605C2 (nl) * 2005-07-25 2007-01-26 Li-Te Chin Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007039256A2 (de) * 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
CN101300024A (zh) * 2005-11-08 2008-11-05 米德列斯公司 对于与免疫刺激性治疗抗体治疗有关的小肠结肠炎的TNF-α阻断剂治疗
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
KR101446510B1 (ko) 2005-12-08 2014-10-20 메다렉스, 엘.엘.시. 푸코실-지엠1에 대한 인간 모노클론 항체 및 항-푸코실-지엠1 사용법
EP1976883B1 (en) 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
BRPI0709481A2 (pt) 2006-04-07 2011-07-19 Government Of The Us Secretary Dept Of Health And Human Services anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
BRPI0714893A2 (pt) 2006-09-05 2013-05-28 Medarex Inc anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
DK2081595T3 (da) 2006-09-26 2019-07-15 Genmab As Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
US8007797B2 (en) 2006-09-28 2011-08-30 Merck Serono S.A. Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
BRPI0718197A2 (pt) 2006-10-02 2014-09-30 Medarex Inc Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
ES2388567T3 (es) 2006-10-19 2012-10-16 Csl Limited Anticuerpos anti-il-13r alfa 1 y usos de los mismos
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
CN101578296A (zh) 2006-11-15 2009-11-11 梅达雷克斯公司 结合btla的人类单克隆抗体及使用方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TWI447124B (zh) 2006-12-01 2014-08-01 Medarex Llc 結合ｃｄ２２的人類抗體與其應用
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
FI20075278A0 (fi) 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2769729B1 (en) 2007-09-04 2019-01-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EA201000718A1 (ru) 2007-11-02 2011-06-30 Новартис Аг Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
KR101463296B1 (ko) 2008-08-05 2014-11-27 노파르티스 아게 보체 단백질 ｃ５를 표적으로 하는 항체의 조성물 및 방법
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
MX2011005691A (es) * 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
CA3053156A1 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
DK2387627T3 (en) * 2009-01-15 2016-07-04 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for producing monoclonal antibodies
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
PL2403878T3 (pl) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. W pełni ludzkie przeciwciała specyficzne dla CADM1
US8597650B2 (en) 2009-04-08 2013-12-03 Olle Hernell Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EA201101572A1 (ru) 2009-04-27 2012-05-30 Новартис Аг Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
EP2445925A1 (en) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Protein purification by caprylic acid (octanoic acid) precipitation
MX2012000851A (es) 2009-07-20 2012-06-08 Squibb Bristol Myers Co Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2480561B1 (en) 2009-09-23 2016-07-13 E. R. Squibb & Sons, L.L.C. Cation exchange chromatography
CN102740887B (zh) * 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
EP2949671A1 (en) 2009-10-12 2015-12-02 Pfizer Inc Cancer treatment
EP4406615A2 (en) 2009-10-26 2024-07-31 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
SI2501822T1 (sl) 2009-11-17 2017-10-30 E. R. Squibb & Sons, L.L.C. Postopki za povečanje produkcije proteina
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
EP2510001B1 (en) 2009-12-08 2015-12-02 AbbVie Deutschland GmbH & Co KG Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
BR112012022672B1 (pt) 2010-03-10 2020-04-14 Genmab As anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US9631018B2 (en) 2010-03-26 2017-04-25 The Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
SG185366A1 (en) 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
WO2011157741A2 (en) 2010-06-15 2011-12-22 Genmab A/S Human antibody drug conjugates against tissue factor
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
HUE031855T2 (en) 2010-08-20 2017-08-28 Novartis Ag Anti-epidermal growth factor receptor 3 (HER3) antibodies
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
ES2644236T3 (es) 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP6342325B2 (ja) 2011-05-25 2018-06-13 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 炎症性障害の治療のための抗ｋｉｒ抗体
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US9365651B2 (en) 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2579042B1 (en) * 2011-10-04 2014-07-09 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CN104114576B (zh) 2011-12-21 2017-04-05 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
LT2807192T (lt) 2012-01-27 2018-07-25 AbbVie Deutschland GmbH & Co. KG Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne Compounds, its conjugates and uses, and methods for doing so
EP3372694A1 (en) 2012-03-05 2018-09-12 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
US20150110779A1 (en) 2012-03-15 2015-04-23 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
JP2015513912A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質の産生のための修飾ポリヌクレオチド
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HUE044612T2 (hu) 2012-05-04 2019-11-28 Pfizer Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP2850102A1 (en) 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
DK3421486T3 (da) 2012-06-22 2023-12-04 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US9790184B2 (en) 2012-07-27 2017-10-17 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
AU2013308595C1 (en) 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN104968678B (zh) 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法
BR112015013861A2 (pt) 2012-12-18 2017-07-11 Novartis Ag composições e métodos para proteínas de ação prolongada
JP6576831B2 (ja) 2012-12-28 2019-09-18 プレシジョン・バイオロジクス・インコーポレイテッド 結腸癌及び膵臓癌の診断ならびに治療のための、ヒト化モノクローナル抗体及び使用方法
CN113735967A (zh) 2013-01-10 2021-12-03 根马布私人有限公司 人类IgG1 FC区变体及其用途
AR095193A1 (es) 2013-02-08 2015-09-30 Novartis Ag Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
EA030830B1 (ru) 2013-02-14 2018-10-31 Бристол-Майерс Сквибб Компани Соединения тубулизина, способы их получения и применение
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
WO2014153150A1 (en) * 2013-03-14 2014-09-25 Lee Delphine J Methods of predicting anti ctla-4 response and recurrence of cancer
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
KR101472903B1 (ko) 2013-05-16 2014-12-16 (주)케어젠 T 세포 활성 억제 펩타이드 및 이의 용도
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
CA2919725C (en) 2013-08-08 2023-04-18 Cytune Pharma An il-15 and il-15r.aplha. sushi domain based modulokines
DK3030262T3 (da) 2013-08-08 2019-12-02 Cytune Pharma Kombineret farmaceutisk sammensætning
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
SG10201801063TA (en) 2013-08-14 2018-04-27 Novartis Ag Methods of treating sporadic inclusion body myositis
HRP20230603T1 (hr) 2013-09-20 2023-09-29 Bristol-Myers Squibb Company Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105636986B (zh) 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
SG10201805933TA (en) 2013-12-24 2018-08-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20220127940A (ko) 2014-03-05 2022-09-20 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US10400038B2 (en) 2014-04-03 2019-09-03 Igm Biosciences, Inc. Modified J-chain
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
JP6894702B2 (ja) 2014-05-13 2021-06-30 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN107073109B (zh) 2014-06-11 2021-08-06 凯西·A·格林 Vista激动剂和拮抗剂抑制或增强体液免疫的用途
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
US10555981B2 (en) 2014-07-16 2020-02-11 Transgene S.A. Oncolytic virus for expression of immune checkpoint modulators
US10765710B2 (en) 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
JP6692343B2 (ja) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG11201700473QA (en) 2014-08-07 2017-02-27 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016022896A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photo-controlled removal of targets in vitro and in vivo
EP3646879B1 (en) 2014-08-12 2024-04-03 Massachusetts Institute Of Technology Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CN106999574B (zh) 2014-10-10 2022-05-24 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
WO2016073401A1 (en) 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
CR20170231A (es) 2014-11-07 2017-09-25 Eleven Biotherapeutics Inc Anticuerpos mejorados contra il-6
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
PE20170782A1 (es) 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US20170355768A1 (en) 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
EP3226900A4 (en) 2014-12-05 2018-09-19 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
IL308119A (en) 2014-12-18 2023-12-01 Amgen Inc Stable frozen formulation for herpes simplex virus
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
CN104479019B (zh) * 2014-12-26 2020-07-21 上海复宏汉霖生物技术股份有限公司 一种抗ctla-4人源抗体
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
BR112017014937A2 (pt) 2015-01-14 2018-03-13 Bristol-Myers Squibb Company dímeros de benzodiazepina ligados em ponte a heteroarileno, conjugados dos mesmos, e métodos de preparação e uso
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
KR20180006367A (ko) * 2015-02-13 2018-01-17 소렌토 쎄라퓨틱스, 인코포레이티드 Ctla4에 결합하는 항체 치료제
EP3262196B1 (en) 2015-02-24 2020-12-09 Adaptive Biotechnologies Corp. Method for determining hla status using immune repertoire sequencing
US10695693B2 (en) 2015-03-13 2020-06-30 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
JP6944924B2 (ja) 2015-03-23 2021-10-06 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓに対する抗体
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
CN107530432B (zh) 2015-04-07 2021-04-27 Cytlimic公司 药物
WO2016164799A1 (en) 2015-04-10 2016-10-13 The Regents Of The University Of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
PT3283107T (pt) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Composições compreendendo uma combinação de ipilimumab e nivolumab
JP6403876B2 (ja) 2015-04-20 2018-10-10 三菱電機株式会社 レーザ装置及び極端紫外光生成装置
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
EP3729967A1 (en) 2015-05-06 2020-10-28 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EP3294334B1 (en) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3718569B1 (en) 2015-05-22 2023-05-03 Translational Drug Development, LLC Benzamide and active compound compositions and methods of use
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
CN107614526A (zh) 2015-06-05 2018-01-19 诺华股份有限公司 靶向骨形成蛋白9(bmp9)的抗体及其方法
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
HUE056491T2 (hu) 2015-06-29 2022-02-28 Bristol Myers Squibb Co Immunterápiás adagolási rendszerek, amelyek tartalmaznak pomalidomid-et és anti-CS1-antitestet rák kezelésére
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
KR20180027576A (ko) 2015-07-14 2018-03-14 브리스톨-마이어스 스큅 컴퍼니 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10660954B2 (en) 2015-07-31 2020-05-26 University Of Florida Research Foundation, Incorporated Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
CN115043944A (zh) 2015-08-03 2022-09-13 诺华股份有限公司 治疗fgf21相关病症的方法
EP3331917A1 (en) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
CA2994918C (en) * 2015-08-11 2024-03-19 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
EP3334761B1 (en) 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US11385231B2 (en) 2015-08-27 2022-07-12 Inserm (Institut National De La Sante Et De La Recherche Scientifique) Methods for predicting the survival time of patients suffering from a lung cancer
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
RU2734777C2 (ru) 2015-09-03 2020-10-23 Оно Фармасьютикал Ко., Лтд. Средство, повышающее иммунитет, для лечения злокачественного новообразования с применением антагониста аллергина-1
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
EP3365062A4 (en) 2015-10-19 2019-07-17 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
CA2998208A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
EP3370733B1 (en) 2015-11-02 2021-07-14 Board of Regents, The University of Texas System Methods of cd40 activation and immune checkpoint blockade
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP2018538263A (ja) 2015-11-18 2018-12-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体の組合せを用いる肺癌の処置法
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
WO2017084078A1 (en) * 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
KR20180083944A (ko) 2015-12-02 2018-07-23 아게누스 인코포레이티드 항체 및 이의 사용 방법
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
KR20180094028A (ko) 2015-12-11 2018-08-22 다이액스 코포레이션 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
CN113633634A (zh) 2016-01-08 2021-11-12 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂
SG10202003099XA (en) 2016-01-08 2020-05-28 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
PL3405212T3 (pl) 2016-01-19 2020-11-16 Pfizer Inc. Szczepionki przeciwnowotworowe
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
EP3407912B1 (en) 2016-01-28 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
WO2017129790A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
AR107708A1 (es) 2016-02-23 2018-05-23 Eleven Biotherapeutics Inc Formulaciones de antagonista de il-6 y sus usos
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
JP7277047B2 (ja) 2016-04-15 2023-05-18 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
PL3449017T3 (pl) 2016-04-29 2022-06-27 Board Of Regents, The University Of Texas System Ukierunkowane pomiary aktywności transkrypcyjnej związanej z receptorami hormonów
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
MX2018013072A (es) 2016-05-09 2019-03-21 Squibb Bristol Myers Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
EP3454909A1 (en) 2016-05-10 2019-03-20 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
AU2017268397B2 (en) 2016-05-18 2023-07-06 Modernatx, Inc. Polynucleotides encoding interleukin-12 (IL12) and uses thereof
WO2017201325A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
WO2017201352A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102369735B1 (ko) 2016-05-20 2022-03-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 암을 치료하기 위한 면역요법과의 글루타메이트 조정제의 용도
EP3463433A1 (en) 2016-05-25 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and compositions for treating cancers
CN109641044A (zh) 2016-05-30 2019-04-16 吉奥瓦科斯公司 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
HRP20230864T1 (hr) 2016-06-02 2023-11-10 Bristol-Myers Squibb Company Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
KR102515509B1 (ko) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR20190015407A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
JP2019521109A (ja) 2016-06-08 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパテ 化学化合物
US20190298705A1 (en) 2016-06-08 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
IL263542B1 (en) 2016-06-14 2024-06-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
US11434269B2 (en) 2016-06-15 2022-09-06 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
TWI793162B (zh) 2016-06-20 2023-02-21 英商克馬伯有限公司 抗體
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
KR20190035714A (ko) 2016-06-30 2019-04-03 온코루스, 인크. 치료 폴리펩티드의 위형된 종양용해성 바이러스 전달
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
CN109618556B (zh) 2016-07-12 2022-10-21 H.隆德贝克有限公司 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
AU2017297603A1 (en) 2016-07-14 2019-02-14 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3490561A4 (en) * 2016-08-01 2020-04-08 Ignyta, Inc. COMBINATIONS FOR THE TREATMENT OF CANCER
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
JP2019528312A (ja) 2016-08-07 2019-10-10 ノバルティス アーゲー ｍＲＮＡ媒介性の免疫化方法
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
CN109790201A (zh) 2016-08-12 2019-05-21 百时美施贵宝公司 纯化蛋白质的方法
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
ES2902179T3 (es) 2016-08-19 2022-03-25 Bristol Myers Squibb Co Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
CN118252927A (zh) 2016-08-19 2024-06-28 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
CA3036997A1 (en) 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CA3038020A1 (en) 2016-09-23 2018-03-29 Merus N.V. Bispecific binding molecules that bind cd137
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
CN110249226B (zh) 2016-10-03 2023-08-25 雅培实验室 评估患者样品中gfap状态的改进方法
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 新規抗ｃｔｌａ４抗体
WO2018070069A1 (ja) 2016-10-11 2018-04-19 サイトリミック株式会社 医薬
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
KR102634093B1 (ko) 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
US11672771B2 (en) 2016-11-04 2023-06-13 Aximmune, Inc. Beta-alethine, immune modulators, and uses thereof
US11124570B2 (en) 2016-11-08 2021-09-21 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CA3043356A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3538140A1 (en) 2016-11-14 2019-09-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
AU2017359944B2 (en) 2016-11-15 2024-07-18 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
IL300095A (en) 2016-11-23 2023-03-01 Translational Drug Dev Llc Compositions of benzamide and an agonist for the cancer necrosis factor receptor superfamily and uses thereof
CN106432499A (zh) * 2016-11-24 2017-02-22 上海美迪西生物医药股份有限公司 Ctla‑4抗体fab在昆虫表达系统中的制备方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
KR20190090823A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
CN110248676A (zh) 2016-12-01 2019-09-17 葛兰素史密斯克莱知识产权发展有限公司 组合疗法
EA201991383A1 (ru) * 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
EP3552126A1 (en) 2016-12-09 2019-10-16 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
EP3555127A1 (en) 2016-12-16 2019-10-23 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110869052A (zh) 2016-12-23 2020-03-06 维图生物制剂公司 癌症的治疗
EP3559029A2 (en) 2016-12-23 2019-10-30 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
JP7217710B2 (ja) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
WO2018129451A2 (en) 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
JP7062010B2 (ja) 2017-01-27 2022-05-02 セルジーン コーポレイション ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
WO2018146148A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146128A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
AU2018219862B2 (en) 2017-02-07 2020-09-17 Nant Holding IP, LLC Maximizing T-cell memory and compositions and methods therefor
KR102572663B1 (ko) 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3366703B1 (en) 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
AU2018227428A1 (en) 2017-02-28 2019-10-17 Bristol-Myers Squibb Company Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
EP3596469A1 (en) 2017-03-12 2020-01-22 Yeda Research and Development Co., Ltd. Methods of diagnosing and prognosing cancer
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
EP3595690A1 (en) 2017-03-15 2020-01-22 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN106916226B (zh) * 2017-03-17 2020-01-14 信达生物制药(苏州)有限公司 以ctla-4为靶点的免疫调节药物治疗结核病的应用
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
CN117024534A (zh) 2017-03-30 2023-11-10 约翰霍普金斯大学 用于纯化生物大分子的超分子高亲和力蛋白结合系统
SG10202110594UA (en) 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
JP7344797B2 (ja) 2017-04-15 2023-09-14 アボット・ラボラトリーズ 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
KR20190137911A (ko) 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
KR20190141223A (ko) 2017-04-26 2019-12-23 브리스톨-마이어스 스큅 컴퍼니 디술피드 결합 환원을 최소화하는 항체 생산 방법
CA3053410A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US11643463B2 (en) * 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
CA3063983A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
KR20220167342A (ko) 2017-05-25 2022-12-20 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EP4245375A3 (en) 2017-05-30 2023-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
KR20200011447A (ko) 2017-05-30 2020-02-03 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
SI3631454T1 (sl) 2017-05-30 2023-12-29 Bristol-Myers Squibb Company Zdravljenje lag-3 pozitivnih tumorjev
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
EP3634584A4 (en) 2017-06-09 2021-04-07 Providence Health & Services - Oregon USE OF CD39 AND CD103 FOR THE IDENTIFICATION OF REACTIVE HUMAN TUMOR CELLS FOR THE TREATMENT OF CANCER
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
CN110785433A (zh) 2017-06-28 2020-02-11 诺华股份有限公司 预防和治疗尿失禁的方法
SI3644999T1 (sl) 2017-06-30 2023-04-28 Celgene Corporation Sestavki in postopki uporabe 2-(4-klorofenil)-N-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoroacetamida
CA3068395A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
EP3649106A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
CN107325181A (zh) * 2017-07-05 2017-11-07 无锡傲锐东源生物科技有限公司 抗ctla4蛋白单克隆抗体及其用途
IL271889B2 (en) 2017-07-10 2023-03-01 Celgene Corp Antisplit compounds and methods of their use
WO2019012371A1 (en) 2017-07-11 2019-01-17 Pfizer Inc. IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT
WO2019014402A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. MODULATORS OF NLRP3
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
WO2019036433A2 (en) * 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
EP3668640A4 (en) 2017-08-18 2021-07-14 The Johns Hopkins University SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
US20210060158A1 (en) 2017-09-19 2021-03-04 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
JP2020536051A (ja) 2017-09-20 2020-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 腫瘍が高いパッセンジャー遺伝子変異量を担持する患者の免疫療法剤
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
KR102429747B1 (ko) 2017-10-13 2022-08-05 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
JP2021501221A (ja) 2017-11-10 2021-01-14 アーモ・バイオサイエンシーズ・インコーポレイテッドＡｒｍｏ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 免疫チェックポイント経路阻害剤と併用したインターロイキン−１０の組成物および使用方法
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
AU2018371212A1 (en) 2017-11-24 2020-06-11 Assistance Publique - Hôpitaux De Paris Methods and compositions for treating cancers
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
EP3721234A1 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
AU2018378971A1 (en) 2017-12-09 2020-01-02 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
DK3710484T3 (da) * 2017-12-20 2023-11-27 Harbour Biomed Shanghai Co Ltd Ctla-4-bindende antistoffer og anvendelser deraf
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
US20210177781A9 (en) 2018-01-12 2021-06-17 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CN111629731A (zh) 2018-01-22 2020-09-04 百时美施贵宝公司 治疗癌症的组合物和方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160755A1 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies
CN111867679A (zh) 2018-03-06 2020-10-30 居里研究所 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
CA3093742A1 (en) 2018-03-12 2019-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
BR112020018480B1 (pt) 2018-03-14 2022-09-27 Surface Oncology, Inc Usos de anticorpos que se ligam a cd39 no tratamento de câncer
CN110272490B (zh) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
KR20200135421A (ko) 2018-03-21 2020-12-02 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
GB2609346B (en) 2018-03-25 2023-06-21 Snipr Biome Aps Treating & preventing microbial infections
CA3094108A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas Systems Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3774882A1 (en) 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
MX2020010606A (es) 2018-04-09 2021-01-15 Eisai R&D Man Co Ltd Compuestos de pladienolida y su uso.
IL304988A (en) 2018-04-12 2023-10-01 Eisai R&D Man Co Ltd Palladianolide history as spliceosome targeting agents for cancer therapy
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US12037344B2 (en) 2018-04-25 2024-07-16 Innate Tumor Immunity, Inc NLRP3 modulators
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
SG11202011568XA (en) 2018-05-23 2020-12-30 Celgene Corp Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
US11439637B2 (en) 2018-05-23 2022-09-13 Celgene Corporation Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
MX2020012674A (es) 2018-05-29 2021-02-09 Bristol Myers Squibb Co Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
TW202015732A (zh) 2018-05-31 2020-05-01 日商小野藥品工業股份有限公司 免疫檢查點阻礙藥的有效性判定用生物標記
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US20210253614A1 (en) 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
AU2019277700A1 (en) 2018-06-01 2020-11-19 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
US20210214410A1 (en) 2018-06-01 2021-07-15 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
KR20210016406A (ko) 2018-06-01 2021-02-15 에자이 알앤드디 매니지먼트 가부시키가이샤 스플라이싱 조정제를 사용하는 방법
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
US20210254069A1 (en) 2018-06-15 2021-08-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
EP3810189A1 (en) 2018-06-19 2021-04-28 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
BR112020027095A2 (pt) 2018-07-09 2021-03-30 Five Prime Therapeutics, Inc. Anticorpos de ligação a ilt4
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
CN112638948A (zh) 2018-07-11 2021-04-09 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN112703011A (zh) 2018-08-06 2021-04-23 国家医疗保健研究所 用于治疗癌症的方法和组合物
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
KR20210045430A (ko) 2018-08-16 2021-04-26 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
WO2020037091A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
CN112888677A (zh) 2018-08-16 2021-06-01 先天肿瘤免疫公司 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
CN113056487A (zh) 2018-09-18 2021-06-29 梅里麦克制药股份有限公司 抗tnfr2抗体及其用途
US20220073638A1 (en) 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
US20210213102A1 (en) 2018-09-21 2021-07-15 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020070053A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
TW202028212A (zh) 2018-10-11 2020-08-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20210340240A1 (en) 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
WO2020086724A1 (en) 2018-10-23 2020-04-30 Bristol-Myers Squibb Company Methods of treating tumor
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
BR112021008057A2 (pt) 2018-10-30 2021-08-10 Genmab A/S método para tratar câncer cervical, e, kit
KR20230051630A (ko) * 2018-10-31 2023-04-18 바이오아트라, 인코퍼레이티드 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
CA3119742A1 (en) 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CA3119467A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
EP3888648A4 (en) 2018-11-27 2022-08-10 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY
ES2971964T3 (es) 2018-11-28 2024-06-10 Inst Nat Sante Rech Med Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113272427A (zh) 2018-11-28 2021-08-17 得克萨斯大学体系董事会 免疫细胞的多重基因组编辑以增强功能性和对抑制环境的抵抗力
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
IL283487B2 (en) 2018-11-30 2024-07-01 Glaxosmithkline Ip Dev Ltd Compounds useful in curing HIV
HRP20230500T1 (hr) 2018-11-30 2023-07-21 Bristol-Myers Squibb Company Antitijelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primjene
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2020123453A2 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
AU2019397062A1 (en) 2018-12-13 2021-05-06 Eisai R&D Management Co., Ltd. Herboxidiene antibody-drug conjugates and methods of use
EP3897624A1 (en) 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor
EP3902529A1 (en) 2018-12-27 2021-11-03 Amgen Inc. Lyophilized virus formulations
EP3902562A1 (en) 2018-12-28 2021-11-03 Transgene SA M2-defective poxvirus
CA3125476A1 (en) 2019-01-03 2020-07-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EA202191903A1 (ru) 2019-01-09 2021-11-12 Селджин Корпорейшн Антипролиферативные соединения и вторые активные агенты для комбинированного применения
US11370777B2 (en) 2019-01-09 2022-06-28 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
CN114409630B (zh) 2019-01-09 2024-04-02 细胞基因公司 包含氧代异吲哚化合物的药物组合物以及使用它的方法
CN113286787A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
EP3911417B1 (en) 2019-01-14 2022-10-26 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators , for use in the treatment of cancer
CN113286786A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
JP7373571B2 (ja) 2019-01-14 2023-11-02 イネイト・テューマー・イミュニティ・インコーポレイテッド がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
JP2022517029A (ja) 2019-01-15 2022-03-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
CA3127236A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
BR112021014911A2 (pt) 2019-02-01 2021-11-23 Glaxosmithkline Ip Dev Ltd Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
EP3930846A1 (en) 2019-03-01 2022-01-05 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN113439123A (zh) 2019-03-05 2021-09-24 安进公司 溶瘤病毒用于治疗癌症的用途
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
AU2020248002A1 (en) 2019-03-26 2021-10-21 The Regents Of The University Of Michigan Small molecule degraders of STAT3
EP3946628A1 (en) 2019-03-28 2022-02-09 Bristol-Myers Squibb Company Methods of treating tumor
US20220041733A1 (en) 2019-03-28 2022-02-10 Bristol-Myers Squibb Company Methods of treating tumor
JP2022527493A (ja) 2019-03-29 2022-06-02 ブリストル－マイヤーズ スクイブ カンパニー クロマトグラフィー樹脂の疎水性を測定する方法
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
CN114126637A (zh) 2019-03-29 2022-03-01 居里研究所 具有经修饰的生物活性的白介素-2变体
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
US20220160692A1 (en) 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
AU2020268199A1 (en) 2019-05-09 2021-11-18 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
EP3968971A1 (en) 2019-05-17 2022-03-23 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
CN114555610A (zh) 2019-05-20 2022-05-27 麻省理工学院 硼酸酯前药及其用途
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020247974A1 (en) 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with collagen binding drug carriers
BR112021024402A2 (pt) 2019-06-03 2022-02-15 Univ Chicago Métodos e composições para tratamento de câncer com adjuvantes direcionados ao câncer
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
EP3983084A1 (en) 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
US20220265590A1 (en) 2019-06-12 2022-08-25 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
EP3990494A1 (en) 2019-06-26 2022-05-04 GlaxoSmithKline Intellectual Property Development Limited Il1rap binding proteins
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
MX2022000550A (es) 2019-07-16 2022-02-10 Univ Michigan Regents Imidazopirimidinas como inhibidores de eed y uso de estas.
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114144436A (zh) 2019-07-24 2022-03-04 H.隆德贝克有限公司 抗mGluR5抗体及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
EP4021580A1 (en) 2019-08-27 2022-07-06 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
EP4031178A1 (en) 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
KR20220100860A (ko) 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. 질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물
EP4031531A1 (en) 2019-09-17 2022-07-27 Bial-R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
WO2021055627A1 (en) 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
AU2020348849A1 (en) 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
US20230192860A1 (en) 2019-09-19 2023-06-22 Bristol-Myers Squibb Company Antibodies Binding to Vista at Acidic pH
AU2020350795A1 (en) 2019-09-22 2022-03-31 Bristol-Myers Squibb Company Quantitative spatial profiling for LAG-3 antagonist therapy
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
KR20220066346A (ko) 2019-09-25 2022-05-24 서피스 온콜로지, 인크. 항-il-27 항체 및 이의 용도
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
EP4048304A1 (en) 2019-10-22 2022-08-31 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
EP4049675A4 (en) 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOREGULATOR
NL2024107B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
NL2024108B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
CN115397472A (zh) 2019-11-04 2022-11-25 思进股份有限公司 抗cd30抗体-药物缀合物及其用于治疗hiv感染的用途
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
JP2023500888A (ja) 2019-11-07 2023-01-11 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
EP3824954A1 (en) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Device, apparatus and method for minibeam radiation therapy
EP4066852A4 (en) 2019-11-27 2024-05-22 NEC Corporation PHARMACEUTICAL COMPOSITION
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
CR20220357A (es) 2019-12-27 2022-08-24 Chugai Pharmaceutical Co Ltd Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
BR112022012918A2 (pt) 2020-01-07 2022-09-06 Univ Texas Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer
EP4087842A1 (en) 2020-01-10 2022-11-16 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP2023512023A (ja) 2020-01-28 2023-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 併用療法及びその使用及び方法
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2021183318A2 (en) 2020-03-09 2021-09-16 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
KR20220151189A (ko) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 증진된 효능제 활성을 갖는 cd40에 대한 항체
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
JP2023519673A (ja) 2020-03-31 2023-05-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 置換ピリミジンおよび使用方法
EP4134134A4 (en) 2020-04-10 2023-12-27 ONO Pharmaceutical Co., Ltd. STING AGONIST COMPOUND
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CA3175499A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
US20230233474A1 (en) 2020-05-28 2023-07-27 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
WO2021242794A2 (en) 2020-05-29 2021-12-02 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
CA3169518A1 (en) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
CN116323607A (zh) 2020-06-10 2023-06-23 施万生物制药研发Ip有限责任公司 用作alk5抑制剂的萘啶衍生物
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
BR112022026090A2 (pt) 2020-06-25 2023-01-17 Celgene Corp Métodos para tratar câncer com terapias de combinação
EP4171652A1 (en) 2020-06-29 2023-05-03 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
US20230266322A1 (en) 2020-06-30 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
BR112023000248A2 (pt) 2020-07-07 2023-01-31 Celgene Corp Composições farmacêuticas compreendendo (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)óxi)metil)benzil)piperazin-1-il)-3-fluorobenzo¬nitrila e métodos de uso das mesmas
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
BR112023000826A2 (pt) 2020-07-21 2023-02-07 Shanghai Junshi Biosciences Co Ltd Anticorpo anti-ctla-4 e uso do mesmo
US20230295146A1 (en) 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
EP4193151A1 (en) 2020-08-04 2023-06-14 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
KR20230042301A (ko) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
WO2022047189A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
EP4232453A1 (en) 2020-10-20 2023-08-30 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
IL302034A (en) 2020-11-04 2023-06-01 Heidelberg Pharma Res Gmbh The composition includes a combination of an immune control inhibitor and a conjugated amatoxin antibody for use in cancer treatment
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
AU2021376218A1 (en) 2020-11-08 2023-06-15 Seagen Inc. Combination Therapy
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CN117580859A (zh) 2020-11-17 2024-02-20 思进股份有限公司 用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
EP4247352A1 (en) 2020-11-18 2023-09-27 Institut Curie Dimers of biguanidines and their therapeutic uses
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022150788A2 (en) 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to receptor pairing
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
CN117529338A (zh) 2021-01-19 2024-02-06 威廉马歇莱思大学 多肽的骨特异性递送
JP2024504696A (ja) * 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
US20220249639A1 (en) 2021-01-22 2022-08-11 Dcprime B.V. Methods of tumor vaccination
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
CN117279664A (zh) 2021-04-10 2023-12-22 普方生物制药美国公司 Folr1结合剂、其偶联物及其使用方法
EP4079311A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
CA3216320A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
BR112023022097A2 (pt) 2021-06-07 2023-12-19 Agonox Inc Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
AU2022289317A1 (en) 2021-06-10 2023-12-14 Ono Pharmaceutical Co., Ltd. Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy
CA3222291A1 (en) 2021-06-14 2022-12-22 Jaime MARINO Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
AR126236A1 (es) 2021-06-25 2023-10-04 Chugai Pharmaceutical Co Ltd Uso del anticuerpo anti-ctla-4
BR112023022992A2 (pt) 2021-06-25 2024-01-23 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4
EP4367269A1 (en) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4380967A1 (en) 2021-08-04 2024-06-12 The Regents of the University of Colorado, a body corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023011879A1 (en) 2021-08-05 2023-02-09 Institut Curie Scanning dynamic device for minibeams production
CN118284623A (zh) 2021-08-23 2024-07-02 伊莫尼塔斯治疗公司 抗cd161抗体及其用途
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4401715A1 (en) 2021-09-17 2024-07-24 Institut Curie Bet inhibitors for treating pab1 deficient cancer
EP4409294A1 (en) 2021-09-30 2024-08-07 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023060136A1 (en) 2021-10-05 2023-04-13 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
IL312027A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culture of immune cells
KR20240099362A (ko) 2021-10-29 2024-06-28 브리스톨-마이어스 스큅 컴퍼니 혈액암에 대한 lag-3 길항제 요법
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
CN113907045B (zh) * 2021-11-09 2023-01-06 派生特（福州）生物科技有限公司 一种新品系猪的培育方法及其应用
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
AU2022396272A1 (en) * 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024046389A1 (zh) * 2022-08-31 2024-03-07 百奥泰生物制药股份有限公司 抗tigit抗体和抗ctla-4抗体联合用于治疗肿瘤中的应用
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2024084013A1 (en) 2022-10-20 2024-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination therapy for the treatment of cancer
WO2024094688A1 (en) 2022-11-01 2024-05-10 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3708238A1 (de) 1987-03-16 1988-09-29 Motoren Werke Mannheim Ag Kraft-waerme-kopplungsanlage
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
DE69032742T2 (de) 1989-08-09 1999-06-17 Rhomed, Inc., Albuquerque, N.Mex. Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE170562T1 (de) 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
ATE196313T1 (de) 1993-06-04 2000-09-15 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
CA2144319A1 (en) 1993-07-09 1995-01-19 George N. Cox Recombinant ctla4 polypeptides and methods for making the same
EP0711345A1 (en) 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0749323B1 (en) 1994-03-08 2000-11-29 Dana-Farber Cancer Institute Methods for modulating t cell anergy
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
WO1996022380A2 (en) 1995-01-20 1996-07-25 Cell Genesys, Inc. Method to improve screening efficiency in fused cells
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5618912A (en) * 1995-05-04 1997-04-08 Pennzoil Products Company Tire sealer and inflator compositions
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0843961B1 (en) 1995-08-29 2007-01-24 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
DE69835145T2 (de) * 1997-02-28 2007-06-14 Kirin Beer K.K. Transgene Mäuse die ein menschliches Antikörper exprimieren
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
AU7228398A (en) 1997-04-11 1998-11-11 John P. Robarts Research Institute, The Lck serine phosphorylation assay for t-cell activation and activation-induced cell death
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6509057B2 (en) 1998-04-01 2003-01-21 Sumitomo Osaka Cement, Co., Ltd. Antibacterial, antifungal or antialgal article and process for producing same
CA2241621A1 (en) 1998-06-26 1999-12-26 National Silicates Ltd. A lubricating method for silicate drilling fluids
DK1137436T3 (da) * 1998-12-03 2008-10-13 Univ California Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
KR100849443B1 (ko) * 1998-12-23 2008-07-31 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
MXPA02001911A (es) * 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9169311B2 (en) 2013-03-15 2015-10-27 Applied Food Biotechnology, Inc. Feline bitter taste receptors and methods
KR102264548B1 (ko) 2014-11-21 2021-06-16 삼성전자주식회사 반도체 패키지 및 그 제조 방법

Also Published As

Publication number Publication date
FR12C0004I1 (ru) 2012-02-24
US6984720B1 (en) 2006-01-10
IL189629A0 (en) 2008-06-05
JP5599158B2 (ja) 2014-10-01
AU7073200A (en) 2001-03-19
EP2829609A1 (en) 2015-01-28
DK1212422T3 (da) 2007-07-02
EP1212422B1 (en) 2007-02-21
EP1792991A1 (en) 2007-06-06
KR100942863B1 (ko) 2010-02-17
NZ517202A (en) 2004-05-28
CY1107628T1 (el) 2013-04-18
LU91928I2 (fr) 2012-03-09
CY2012002I2 (el) 2020-05-29
MXPA02001911A (es) 2003-07-21
AU2006201520B2 (en) 2009-03-19
CA2381770A1 (en) 2001-03-01
DE122012000001I1 (de) 2012-03-15
KR20020047132A (ko) 2002-06-21
AU2006201520A1 (en) 2006-05-11
AU2006201520B9 (en) 2009-08-27
WO2001014424A2 (en) 2001-03-01
AU784012B2 (en) 2006-01-12
DE60033530D1 (de) 2007-04-05
AU2009202447B2 (en) 2011-11-24
CA2381770C (en) 2007-08-07
CY2012002I1 (el) 2016-12-14
KR20060100950A (ko) 2006-09-21
ATE354655T1 (de) 2007-03-15
BE2012C001I2 (ru) 2019-10-16
KR20090036598A (ko) 2009-04-14
CA2589418A1 (en) 2001-03-01
JP2009213478A (ja) 2009-09-24
JP2012100674A (ja) 2012-05-31
CN102766210A (zh) 2012-11-07
CN1371416B (zh) 2012-10-10
KR100996759B1 (ko) 2010-11-25
PT1212422E (pt) 2007-04-30
JP4093757B2 (ja) 2008-06-04
HK1048831A1 (en) 2003-04-17
CN102766210B (zh) 2015-07-08
EP3214175A1 (en) 2017-09-06
CN1371416A (zh) 2002-09-25
ZA200201190B (en) 2003-05-28
ES2282133T3 (es) 2007-10-16
FR12C0004I2 (fr) 2013-01-11
IL148079A (en) 2008-04-13
JP2004512005A (ja) 2004-04-22
EP1212422A2 (en) 2002-06-12
JP2006151993A (ja) 2006-06-15
DE60033530T2 (de) 2007-10-31
AU2009202447A1 (en) 2009-07-09
WO2001014424A3 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
IL129592A0 (en) 5-HT1f agonists
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
PL328858A1 (en) Immunogenous peptides
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
UA48940C2 (ru) Рекомбинантные антитела против ил4, применяемые для лечения заболеваний, опосредуемых ил4
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
PL340459A1 (en) Agonists of 5ht1f
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
NO20005548D0 (no) Mykobakterieinhibitorer
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
GB9715177D0 (en) Medicament
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed